APG-3288

· Ascentage Pharma Group Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for APG-3288, covering 2026-02-20 to 2026-02-20. Get the full timeline:

Most recent: Clinical Trial Update: A Study of APG-3288 in Relapsed/Refractory Blood Cancers [Phase 1]